Literature DB >> 30963285

Treatment of infant formula with patiromer dose dependently decreases potassium concentration.

Neil J Paloian1, Barbara Bowman2, Sharon M Bartosh2.   

Abstract

BACKGROUND: Hyperkalemia is a potentially life-threatening complication of chronic kidney disease (CKD). Dietary potassium restriction is challenging in infants despite low-potassium formulas. Decreasing potassium in formula using patiromer, a new calcium-based cation exchange polymer may be one option to accomplish this; however, data confirming efficacy is lacking.
METHODS: Varying doses of patiromer were added to prepared Similac Advance and Similac PM 60/40. Measurements of potassium, calcium, sodium, magnesium, and phosphorus were obtained at baseline and at 30 min, 60 min, and 24 h following patiromer administration.
RESULTS: Following pre-treatment with patiromer, the potassium concentration of both formulas decreased. This effect was mild with the lowest dose but increased in a dose-dependent fashion. Treating for 60 min or 24 h did not yield substantially greater effects than treating for 30 min. Calcium levels increased in both formula groups, mostly in a dose-dependent fashion. Changes in magnesium, sodium, and phosphorus were also seen after patiromer pre-treatment.
CONCLUSIONS: Pre-treatment with patiromer decreases the potassium concentration of infant formula. Calcium levels increased after treatment as expected with the majority of ion exchange occurring in 30 min. Treatment of formula with patiromer shows promise as a unique option for managing hyperkalemia.

Entities:  

Keywords:  Formula; Hyperkalemia; Patiromer; Potassium

Mesh:

Substances:

Year:  2019        PMID: 30963285     DOI: 10.1007/s00467-019-04232-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  19 in total

1.  Management of hyperkalemia with a cation-exchange resin.

Authors:  L SCHERR; D A OGDEN; A W MEAD; N SPRITZ; A L RUBIN
Journal:  N Engl J Med       Date:  1961-01-19       Impact factor: 91.245

2.  Renal formulas pretreated with medications alters the nutrient profile.

Authors:  Jacob M Taylor; Leah Oladitan; Susan Carlson; Jill M Hamilton-Reeves
Journal:  Pediatr Nephrol       Date:  2015-05-01       Impact factor: 3.714

3.  Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.

Authors:  George L Bakris; Bertram Pitt; Matthew R Weir; Mason W Freeman; Martha R Mayo; Dahlia Garza; Yuri Stasiv; Rezi Zawadzki; Lance Berman; David A Bushinsky
Journal:  JAMA       Date:  2015-07-14       Impact factor: 56.272

4.  Effect of Patiromer on Urinary Ion Excretion in Healthy Adults.

Authors:  David A Bushinsky; David M Spiegel; Coleman Gross; Wade W Benton; Jeanene Fogli; Kathleen M Hill Gallant; Charles Du Mond; Geoffrey A Block; Matthew R Weir; Bertram Pitt
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-27       Impact factor: 8.237

5.  Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease.

Authors:  Susan L Furth; Alison G Abraham; Judith Jerry-Fluker; George J Schwartz; Mark Benfield; Frederick Kaskel; Craig Wong; Robert H Mak; Marva Moxey-Mims; Bradley A Warady
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-12       Impact factor: 8.237

6.  Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

Authors:  Matthew R Weir; George L Bakris; David A Bushinsky; Martha R Mayo; Dahlia Garza; Yuri Stasiv; Janet Wittes; Heidi Christ-Schmidt; Lance Berman; Bertram Pitt
Journal:  N Engl J Med       Date:  2014-11-21       Impact factor: 91.245

7.  Pretreatment of formula with sodium polystyrene sulfonate to reduce dietary potassium intake.

Authors:  T E Bunchman; E G Wood; M H Schenck; K A Weaver; B L Klein; R E Lynch
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

Review 8.  Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review.

Authors:  Ziv Harel; Shai Harel; Prakesh S Shah; Ron Wald; Jeffrey Perl; Chaim M Bell
Journal:  Am J Med       Date:  2013-01-12       Impact factor: 4.965

9.  Complications following oral administration of exchange resins in extremely low-birth-weight infants.

Authors:  A Ohlsson; M Hosking
Journal:  Eur J Pediatr       Date:  1987-11       Impact factor: 3.183

10.  Pretreatment of enteral nutrition with sodium polystyrene sulfonate: effective, but beware the high prevalence of electrolyte derangements in clinical practice.

Authors:  Krisha Le Palma; Elisha Rampolla Pavlick; Lawrence Copelovitch
Journal:  Clin Kidney J       Date:  2017-12-21
View more
  2 in total

1.  Nutritional management of the infant with chronic kidney disease stages 2-5 and on dialysis.

Authors:  Vanessa Shaw; Caroline Anderson; An Desloovere; Larry A Greenbaum; Dieter Haffner; Christina L Nelms; Fabio Paglialonga; Nonnie Polderman; Leila Qizalbash; José Renken-Terhaerdt; Stella Stabouli; Jetta Tuokkola; Johan Vande Walle; Bradley A Warady; Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2022-04-05       Impact factor: 3.714

Review 2.  The dietary management of potassium in children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce.

Authors:  An Desloovere; José Renken-Terhaerdt; Jetta Tuokkola; Vanessa Shaw; Larry A Greenbaum; Dieter Haffner; Caroline Anderson; Christina L Nelms; Michiel J S Oosterveld; Fabio Paglialonga; Nonnie Polderman; Leila Qizalbash; Bradley A Warady; Rukshana Shroff; Johan Vande Walle
Journal:  Pediatr Nephrol       Date:  2021-03-17       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.